Citation: | Xiao-na JIN, Nai-xin LIANG, Meng-zhao WANG, Bing JIA, Xi-min SHI, Shan-qing LI, Fang LI, Fan WANG, Zhao-hui ZHU. Integrin Receptor Imaging 99mTc-3PRGD2 SPECT/CT in Diagnosis and Lymph Node Staging of Non-Small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(5): 327-333. DOI: 10.3969/j.issn.1674-9081.2016.05.002 |
[1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61:69-90.
|
[2] |
Giaccone G. 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer[J]. J Natl Cancer Inst, 2007, 99:1741-1743. DOI: 10.1093/jnci/djm245
|
[3] |
Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT[J]. N Engl J Med, 2009, 361:32-39. DOI: 10.1056/NEJMoa0900043
|
[4] |
Vansteenkiste J, Fischer BM, Dooms C, et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer:systematic review[J]. Lancet Oncol, 2004, 5:531-540. DOI: 10.1016/S1470-2045(04)01564-5
|
[5] |
Jia B, Liu Z, Zhu Z, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD2 in non-human primates[J]. Mol Imaging Biol, 2011, 13:730-736. DOI: 10.1007/s11307-010-0385-y
|
[6] |
Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer:a multicenter study[J]. J Nucl Med, 2012, 53:716-722. DOI: 10.2967/jnumed.111.098988
|
[7] |
Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins[J]. J Biol Chem, 2000, 275:21785-21788. DOI: 10.1074/jbc.R000003200
|
[8] |
Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated αⅤβ3 integrin in cancer patients by positron emission tomography and[18F]Galacto-RGD[J]. PLOS Med, 2005, 2:244-252. DOI: 10.1371/journal.pmed.0020244
|
[9] |
Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokine-tic and dosimetric studies of (18)F-FPPRGD2:a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels[J]. Radiology, 2011, 260:182-191. DOI: 10.1148/radiol.11101139
|
[10] |
Iagaru A, Mosci C, Shen B, et al. (18)F-FPPRGD2 PET/CT:pilot phase evaluation of breast cancer patients[J]. Radiology, 2014, 273:549-559. DOI: 10.1148/radiol.14140028
|
[11] |
McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers[J]. J Nucl Med, 2008, 49:1664-1667. DOI: 10.2967/jnumed.108.052126
|
[12] |
Doss M, Kolb HC, Zhang JJ, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans[J]. J Nucl Med, 2012, 53:787-795. DOI: 10.2967/jnumed.111.088955
|
[13] |
Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination[J]. J Nucl Med, 2013, 54:691-698. DOI: 10.2967/jnumed.112.113563
|
[14] |
Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer:a proof-of-concept study to evaluate 99mTc-NC100692[J]. J Nucl Med, 2006, 47:1434-1439.
|
[15] |
Shi J, Wang L, Kim YS, et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers[J]. J Med Chem, 2008, 51:7980-7990. DOI: 10.1021/jm801134k
|
[16] |
Liu Z, Jia B, Shi J, et al. Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature[J]. Bioconjug Chem, 2010, 21:548-555. DOI: 10.1021/bc900547d
|
[17] |
Wolfenson H, Iskratsch T, Sheetz MP. Early events in cell spreading as a model for quantitative analysis of biomechanical events[J]. Biophys J, 2014, 107:2508-2514. DOI: 10.1016/j.bpj.2014.10.041
|
[18] |
van den Hoogen C, van der Horst G, Cheung H, et al. Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer[J]. Am J Pathol, 2011, 179:2559-2568. DOI: 10.1016/j.ajpath.2011.07.011
|
[19] |
Jin X, Meng Y, Zhu Z, et al. Elevated 99mTc-3PRGD2 activity in benign metastasizing leiomyoma[J]. Clin Nucl Med, 2013, 38:117-119. DOI: 10.1097/RLU.0b013e318279f14d
|
[20] |
Deppen S, Putnam JB Jr, Andrade G, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease[J]. Ann Thorac Surg, 2011, 92:428-433. DOI: 10.1016/j.athoracsur.2011.02.052
|
[21] |
Miller JC, Pien HH, Sahani D, et al. Imaging angiogenesis:applications and potential for drug development[J]. J Natl Cancer Inst, 2005, 97:172-187. DOI: 10.1093/jnci/dji023
|
[1] | YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216 |
[2] | ZHU Shikun, ZHANG Shu, LUO Yaping. SPECT/CT in Localization of Sentinel Lymph Node of Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 795-801. DOI: 10.12290/xhyxzz.2023-0170 |
[3] | GAO Yuanjing, ZHU Qingli, JIANG Yuxin. Research Progress of Ultrasound Radiomics in Predicting Axillary Lymph Node Metastasis of Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 989-993. DOI: 10.12290/xhyxzz.2021-0187 |
[4] | LIU Yanting, ZHANG Lu, CHEN Miao, ZHANG Yan, WEI Chong, PAN Boju, ZHAO Jiawei. A Case of Small B-cell Lymphocytic Lymphoma Diagnosed One Year after Evans Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 423-426. DOI: 10.12290/xhyxzz.20200063 |
[5] | XIAO Nan, LI Zhanfeng, YAO Jianxin, PAN Zhiyao, YAO Zhifeng. Long Non-coding RNA and Cancer Stem Cells[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 373-379. DOI: 10.12290/xhyxzz.20190231 |
[6] | PENG Li, ZHAO Jia-lin, ZHAO Da-chun, ZHANG Zhen, MAO Feng, SUN Qiang. Clinicopathological Features and Lymph Node Metastasis-related Factors of Primary Neuroendocrine Breast Cancer and Invasive Breast Cancer of Nonspecial Type: A Case-control Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 122-128. DOI: 10.12290/xhyxzz.20190108 |
[7] | ZHANG Lu, ZHOU Wei, PENG Yan, ZHAN Wei-wei. Efficacy of Percutaneous Laser Ablation in the Treatment of Cervical Metastatic Lymph Nodes after the Surgery of Papillary Thyroid Carcinoma: A Prospective Cohort Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 67-72. DOI: 10.12290/xhyxzz.20190238 |
[8] | Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015 |
[9] | Yan-na ZHANG, Chang-jun WANG, Yi-dong ZHOU, Feng MAO, Qiang SUN, Ya-lan BI, Zhi-yong LIANG. Axillary Lymph Node Metastasis of Invasive Micropapillary Carcinoma and Invasive Carcinoma of No Special Type: A Case-control Study[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(3): 166-172. DOI: 10.3969/j.issn.1674-9081.2015.03.002 |
[10] | Ming-yang LIU, Jie CHEN, Jian GUAN. Local Injections of Cholesterol-conjugated let-7a Mimics Inhibit Tumor Growth and Metastasis of Hepatocellular Carcinoma in a Subcutaneous Xenograft Nude Mouse Model by Targeting K-Ras, H-Ras, and N-Ras[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 133-139. DOI: 10.3969/j.issn.1674-9081.2015.02.012 |